The majority prostate cancers are indolent and do not affect patient's survivals, yet the patients are subjected to overtreatment suffering from treatment side effects, affecting patient's quality of life. Current cancer characters such as grade, stage, serum PSA and nomogram only predict clinical behavior to a certain degree, and do not sufficiently distinguish patients with aggressive (e.g. metastatic) or less aggressive tumors. Developing biomarkers to accurately stratify these patients become urgent task. Thus we propose to use systematic approaches to define protein and pathway network signatures that can distinguish indolent and a form of aggressive, metastatic, prostate cancer applying our Novel Proteomic Pathway array integrated with genomics via bioinformatics. Specifically, we will use a novel proteomic pathway array to identify proteins in key cellular signaling pathways that are differentially expressed or phosphorylated in non-metastatic vs. cancer with metastatic potential. Next, we will determine the association of signal pathway proteins with the clinical outcome of metastasis using high throughput tissue micro arrays. The functional relevance of the proteins identified will be tested in vitro and in vivo. Overall this study uses a unique proteomics and systems biology approach to identifying new biomarkers, and possible therapeutic targets, for metastatic prostate cancer through the elucidation of distinct regulatory network that underlies the biology of the prostate cancer. The advantage of combined expertise of our highly productive and collaborative researchers integrating various high through proteomic and genomic platform with innovative bioinformatics approaches will ensure the successful execution of this proposal. The biomarkers identified from this proposal will greatly improve current strategies to stratify prostate cancer patients between non-metastatic and metastatic disease.
This study will lead to the discovery of novel signal pathway proteins and networks associated with indolent or aggressive (metastatic) prostate cancer and will generate clinically relevant information that may lead to the development of biomarkers for early detection of aggressive prostate cancer. The functional study of these signal transduction proteins may lead to development of novel pathway based treatment strategies for prostate cancer. These research activities are vital to reducing the cancer outcome gaps.
| Liang, Jiaqian; Li, Xin; Li, Yirong et al. (2015) LEF1 targeting EMT in prostate cancer invasion is mediated by miR-181a. Am J Cancer Res 5:1124-32 |
| Liang, Jiaqian; Li, Yirong; Daniels, Garrett et al. (2015) LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a. Mol Cancer Res 13:681-8 |
| Daniels, Garrett; Jha, Ruchi; Shen, Ying et al. (2014) Androgen receptor coactivators that inhibit prostate cancer growth. Am J Clin Exp Urol 2:62-70 |
| Daniels, Garrett; Gellert, Lan Lin; Melamed, Jonathan et al. (2014) Decreased expression of stromal estrogen receptor ? and ? in prostate cancer. Am J Transl Res 6:140-6 |
| Ren, Qinghu; Liang, Jiaqian; Wei, Jianjun et al. (2014) Epithelial and stromal expression of miRNAs during prostate cancer progression. Am J Transl Res 6:329-39 |
| Daniels, Garrett; Li, Yirong; Gellert, Lan Lin et al. (2014) TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Endocr Relat Cancer 21:127-42 |
| Wu, Xinyu; Daniels, Garrett; Lee, Peng et al. (2014) Lipid metabolism in prostate cancer. Am J Clin Exp Urol 2:111-20 |
| Singh, Mandeep; Jha, Ruchi; Melamed, Jonathan et al. (2014) Stromal androgen receptor in prostate development and cancer. Am J Pathol 184:2598-607 |
| Daniels, Garrett; Pei, Zhiheng; Logan, Susan K et al. (2013) Mini-review: androgen receptor phosphorylation in prostate cancer. Am J Clin Exp Urol 1:25-9 |
